# OnCo record datopotamab-deruxtecan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/datopotamab-deruxtecan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "datopotamab-deruxtecan" ;
  schema:name "Datopotamab deruxtecan"@en ;
  schema:description "Datopotamab deruxtecan (Datroway) is the second TROP2 ADC and shares Enhertu's payload. In 2026 it became a first-line option for triple-negative breast cancer patients who cannot receive immunotherapy."@en ;
  schema:url <https://onco.cc/drugs/datopotamab-deruxtecan/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Datopotamab_deruxtecan> ;
  owl:sameAs <http://www.wikidata.org/entity/Q132069567> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Datopotamab%20deruxtecan>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22DATROWAY%22>, <https://www.ema.europa.eu/en/medicines/human/EPAR/datroway> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Datroway" ;
  onco:approval "US 2025: HR+/HER2- metastatic breast cancer after endocrine therapy and chemotherapy", "US 2025: EGFR-mutant NSCLC after EGFR TKI and platinum chemotherapy", "US 2026: First-line unresectable/metastatic TNBC, PD-1/PD-L1 inhibitor ineligible", "EU 2025: HR+/HER2- mBC after endocrine + chemo; 4 Apr 2025", "EU 2025: HR-positive, HER2-negative unresectable or metastatic breast cancer after endocrine therapy and at least one line of chemotherapy; marketing authorisation issued 4 April 2025. No triple-negative indication in the EU on 24 September 2026" ;
  onco:acceleratedApproval "US 2025-06-23: Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy." ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/pdl1-high-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/trop2/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/ggfg/> ;
  onco:trials <https://onco.cc/trials/tropion-breast01/>, <https://onco.cc/trials/tropion-breast02/>, <https://onco.cc/trials/tropion-breast05/>, <https://onco.cc/trials/tropion-lung01/>, <https://onco.cc/trials/nct06350097/>, <https://onco.cc/trials/nct06564844/>, <https://onco.cc/trials/nct06417814/>, <https://onco.cc/trials/nct05215340/>, <https://onco.cc/trials/nct05555732/>, <https://onco.cc/trials/nct06357533/>, <https://onco.cc/trials/nct07291037/>, <https://onco.cc/trials/nct07098338/>, <https://onco.cc/trials/nct04644068/>, <https://onco.cc/trials/nct05061550/>, <https://onco.cc/trials/nct05489211/>, <https://onco.cc/trials/nct05687266/>, <https://onco.cc/trials/nct06130553/>, <https://onco.cc/trials/nct05417594/>, <https://onco.cc/trials/nct05460273/>, <https://onco.cc/trials/nct03742102/>, <https://onco.cc/trials/diamond/>, <https://onco.cc/trials/nct06112379/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-tropion-breast01-china-cohort-esmo-open-2026/> .